MUMBAI – India’s fast-emerging pharmaceutical and biosimilar maker Intas Pharmaceuticals Ltd. expects to fill a significant need gap with its Indian launch of Razumab, the world’s first biosimilar version of ranibizumab, branded Lucentis by Novartis AG.
The VEGF-A-inhibiting antibody fragment is mostly used to treat neovascular (wet) age-related macular degeneration (AMD) but is also used in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?